Document:

Exhibit 10.5

 

[Certain
portions of this exhibit have been redacted as they are both not material and are of the type of information that the Company treats
as private or confidential. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the SEC upon its request.]

 

LIMITED EXCLUSIVE

PATENT LICENSE AGREEMENT

 

For

 

DIAGNOSTIC KIOSK

For Environmental Surveillance, Food Testing, and

Human Clinical Diagnostics

 

Between

 

LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

 

and

 

BIONOMICS DIAGNOSTICS

 

LLNL Case No. TL02679-0.0

 

Lawrence Livermore National Laboratory

Industrial Partnerships Office

P.O. Box 808, L-795, Livermore, CA 94551

 

May 20, 2015

 

     

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

TABLE OF CONTENTS

 

	1.	BACKGROUND	1
	2.	DEFINITIONS	2
	3.	LICENSE
                                            GRANT	6
	4.	SUBLICENSING
                                            RIGHTS AND OBLIGATIONS	6
	5.	FEES,
                                            ROYALTIES, AND PAYMENTS	7
	6.	DUE
                                            DILIGENCE	9
	7.	ROYALTY
                                            AND PROGRESS REPORTS	10
	8.	BOOKS
                                            AND RECORDS	12
	9.	LIFE
                                            OF THE AGREEMENT	13
	10.	TERMINATION	13
	11.	DISPOSITION
                                            OF LICENSED PRODUCTS ON HAND UPON TERMINATION	14
	12.	PATENT
                                            PROSECUTION AND MAINTENANCE	14
	13.	PATENT
                                            INFRINGEMENT	15
	14.	USE
                                            OF NAMES AND TRADEMARKS	16
	15.	LIMITED
                                            WARRANTY	17
	16.	INDEMNIFICATION	18
	17.	INSURANCE	18
	18.	WAIVER	20
	19.	ASSIGNABILITY	20
	20.	LATE
                                            PAYMENTS	20
	21.	NOTICES	20
	22.	GOVERNING
                                            LAWS; VENUE; ATTORNEYS FEES	21
	23.	PATENT
                                            MARKING	21
	24.	GOVERNMENT
                                            APPROVAL OR REGISTRATION	22
	25.	COMPLIANCE
                                            WITH LAWS	22
	26.	FORCE
                                            MAJEURE	22
	27.	UNITED
                                            STATES PREFERENCE	23
	28.	PROPRIETARY
                                            INFORMATION	23
	29.	MISCELLANEOUS	23

	Exhibit A – Licensed Patents	25
	Exhibit B - Rights Granted And Performance Obligations	26
	Exhibit C - Fees And Royalties Notice	28
	Exhibit D - Mutual Nondisclosure Agreement	31

 

    
	15GM0520	TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

LIMITED EXCLUSIVE PATENT LICENSE AGREEMENT

For DIAGNOSTIC KIOSK

For Environmental Surveillance, Food Testing,
and Human Clinical Diagnostics

 

This license agreement (“Agreement”)
is effective on the Effective Date by and between Lawrence Livermore National Security, LLC (“LLNS”) under its U.S.
Department of Energy (“DOE”) Contract No. DE-AC52-07NA27344 to manage and operate Lawrence Livermore National Laboratory
(“LLNL”), and Bionomics Diagnostics (“LICENSEE”), a Canadian corporation having its principal place
of business at [Redacted - Address]. LLNS is a limited liability company organized in the State of Delaware, with its principal
office at 2300 First Street, Suite 204, Livermore, California 94550 3153. LLNS and LICENSEE are referred to jointly as “Parties.”
This Agreement and the resulting license are subject to overriding obligations to the Federal Government pursuant to the provisions of
LLNS’s Contract No. DE-AC52-07NA27344 with the DOE for the operation of the LLNL and DOE’s grant of patent rights to LLNS.

 

		1.	BACKGROUND

 

		1.1	Certain
                                            inventions characterized as the Diagnostic Kiosk Technology (“Invention”) described
                                            in LLNL patent applications and patents listed in Exhibit A (LICENSED PATENTS), which
                                            may be useful for diagnosing diseases, were made at LLNL and are covered by LLNS Patent Rights
                                            as defined in Article 2 (DEFINITIONS).

 

		1.2	LICENSEE
                                            entered into a Mutual Nondisclosure Agreement provided in Exhibit D (MUTUAL NONDISCLOSURE
                                            AGREEMENT), which is incorporated herein, that allowed LICENSEE to evaluate its interest
                                            in taking a license to the Invention.

 

		1.3	LLNS grants
                                            to the U.S. Government a non-transferable, paid-up, nonexclusive, irrevocable license to
                                            use the Invention by, or on behalf of, the U.S. Government throughout the world.

 

		1.4	LICENSEE
                                            requested certain rights from LLNS to commercialize the Invention. LICENSEE submitted
                                            a commercialization plan to LLNS on February 2, 2015, and executed Option Agreement
                                            No. AL00154 with LLNS on March 19, 2015. LICENSEE sent its notification to exercise
                                            its option on March 27, 2015.

 

		1.5	LLNS wishes
                                            to respond to LICENSEE’s request by granting the following rights to LICENSEE
                                            so that the products and other benefits derived from the Invention can be enjoyed by
                                            the general public.

 

		1.6	The scope
                                            of such rights granted by LLNS is intended to extend to the scope of the patents and patent
                                            applications pertaining to the Invention, but only to the extent that LLNS has Valid Claims
                                            of such Patent Rights.

 

    
	15GM0520	1	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		1.7	LLNS has
                                            informed LICENSEE and LICENSEE understands that the Invention is a research
                                            product from a national laboratory and requires additional development for its commercialization.
                                            LICENSEE agrees it is solely responsible for the additional development of the Invention
                                            for commercialization purposes.

 

		1.8	LICENSEE is a “small
                                            entity” as defined in 37 CFR § 1.27.

 

		1.9	LICENSEE is a “small
                                            business firm” as defined at Section 2 of Pub. L. 85-536 (15 U.S.C. § 632).

 

		1.10	Both
                                            Parties recognize that earned royalties due under this Agreement will be based on LICENSEE’s
                                            last act of infringement of Patent Rights within the control of LICENSEE, regardless
                                            of whether LICENSEE had control over prior infringing acts.

 

		1.11	The Parties
                                            intend that royalties due under this Agreement will be calculated and paid on Sales of the
                                            final product or service by LICENSEE.

 

		1.12	LICENSEE
                                            recognizes the need to practice due diligence in the development of the patents licensed
                                            under this Agreement to maintain the license. In addition, both Parties acknowledge that
                                            the U.S. Government has certain march-in rights in accordance with 48 CFR § 27.304-1
                                            (g) and 15 U.S.C. §§ 3710a(b)(1)(B) and (C).

 

THEREFORE, the Parties agree as follows:

 

		2.	DEFINITIONS

 

As used in this Agreement, the following terms, whether
used in the singular or plural, will have the following meanings:

 

		2.1	“Affiliate”
                                            of LICENSEE means any entity which, directly or indirectly, Controls LICENSEE,
                                            is Controlled by LICENSEE, or is under common Control with LICENSEE. “Control”
                                            means (i) having the actual, present capacity to elect a majority of the directors of
                                            such affiliate, (ii) having the power to direct at least forty percent (40%) of the
                                            voting rights entitled to elect directors, or (iii) in any country where the local law
                                            will not permit foreign equity participation of a majority, ownership or control, directly
                                            or indirectly, of the maximum percentage of such outstanding stock or voting rights permitted
                                            by local law. LICENSEE does not include “Affiliate.”

 

    
	15GM0520	2	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		2.2	“Effective Date” means
                                            the date of execution by the last signing Party and payment of the License Issue Fee.

 

		2.3	“Fields of Use” is the
                                            application or use defined in Exhibit B (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS).

 

		2.4	“Joint
                                            Venture” means any separate entity established pursuant to an agreement between a third
                                            party and LICENSEE and/or sublicensee to constitute a vehicle for a joint effort,
                                            in which the separate entity manufactures, uses, purchases, Sells, or acquires Licensed Products
                                            from LICENSEE. LICENSEE does not include “Joint Venture.”

 

		2.5	“Licensed
                                            Method” means any process or method the use or practice of which, but for the license
                                            granted in this Agreement, would infringe, or contribute to, or induce the infringement of,
                                            any Patent Rights.

 

		2.6	“Licensed Patents” means:

 

		2.6.1	U.S.
                                            patents and U.S. patent applications specified in Exhibit A (LICENSED PATENTS), and
                                            U.S. patents resulting from these applications, continuations of these applications, divisions,
                                            and continuation-in-part applications resulting from these applications only to the extent,
                                            however, that Valid Claims in the continuation-in-part applications are entirely supported
                                            in the specification and entitled to the priority date of the parent application;

 

		2.6.2	reissues of 2.6.1.

 

		2.7	“Licensed
                                            Product” means all kits, compositions of matter, materials, articles of manufacture,
                                            and products the manufacture, use, Sale, offer for Sale, or import of which, but for the
                                            license granted in this Agreement, would infringe, or contribute to or induce the infringement
                                            of any Patent Rights were they issued at the time of infringement in that country, or would
                                            require the performance of the Licensed Method.

 

		2.8	“Licensed Service” means
                                            the use of Licensed Products or Licensed Method to provide a service.

 

    
	15GM0520	3	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		2.9	“Net
                                            Invoice Price” means the gross invoice price charged and the value of any other consideration
                                            received by LICENSEE and/or a sublicensee for a Licensed Product or Licensed Service
                                            or for any exploitation of a Licensed Product or Licensed Service, less the following items,
                                            but only to the extent that they actually pertain to the disposition of such Licensed Product
                                            or any exploitation of the Licensed Product or Licensed Service, and are separately billed:

 

		2.9.1	Allowances actually granted
                                            to customers for rejections, returns, and prompt payment and volume discounts;

 

		2.9.2	Freight, transport packing,
                                            insurance charges associated with transportation; and

 

		2.9.3	Taxes,
                                            tariffs or import/export duties based on Sales when included in the gross invoice price,
                                            but not value-added taxes or taxes assessed on income derived from Sales.

 

		2.10	“Net
                                            Sale” means the Net Invoice Price, except in the instances described in Subparagraphs (2.10.1),
                                            (2.10.2), (2.10.3) and (2.10.4) of this Paragraph.

 

		2.10.1	For
                                            any Relationship-Influenced Sale of a Licensed Product or Licensed Service, Net Sales will
                                            be based on the Net Invoice Price at which the Relationship-Influenced Sale Purchaser resells
                                            such Licensed Product or Licensed Service;

 

		2.10.2	In
                                            those instances where Relationship-Influenced Sale Purchaser combines such Licensed Product
                                            or Licensed Service in any manner with any other product or service, Net Sales will be the
                                            Net Invoice Price of the combined product or service;

 

		2.10.3	In
                                            those instances where Licensed Product or Licensed Service is not Sold, but is otherwise
                                            exploited, the Net Sales for such Licensed Product or Licensed Service will be the Net Invoice
                                            Price of products or services of Similar kind and quality, Sold in Similar quantities, currently
                                            being offered for Sale by LICENSEE and/or any sublicensee. “Similar,”
                                            as it relates to products, means only: (i) Cepheid’s GeneXpert® IV system
                                            with the Xpert® MRSA/SA SSTI consumable, (ii) bioMérieux’s FilmArrayTM
                                            system with the Blood Culture Identification (BCID) Panel, or (iii) any product
                                            that is a later generation or successor to the foregoing products. Where such products or
                                            services are not currently being offered for Sale by LICENSEE and/or any sublicensee, the
                                            Net Sales for Licensed Product or Licensed Service otherwise exploited, for the purpose of
                                            computing royalties, will be the average Net Invoice Price at which products or services
                                            of similar kind and quality, Sold in similar quantities, are then currently being offered
                                            for Sale by other manufacturers. Where such products or services are not currently Sold or
                                            offered for Sale by LICENSEE and any sublicensees, or others, then the Net Sales will be
                                            LICENSEE’s and/or any sublicensee’s cost of manufacture of Licensed Product or
                                            the cost of conducting the service, determined by LICENSEE’s and/or any sublicensee’s
                                            customary accounting procedures, plus forty percent (40%);

 

    
	15GM0520	4	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		2.10.4	In
                                            those instances where LICENSEE or a sublicensee acquires and subsequently Sells Licensed
                                            Product or Licensed Service previously Sold by LICENSEE, Net Sales will mean the Net
                                            Invoice Price upon Sale of such acquired Licensed Product or Licensed Service by LICENSEE
                                            or the sublicensee, less any amounts paid to LLNS on account of earlier Sale or other exploitation
                                            of the acquired Licensed Product or Licensed Service.

 

		2.11	“New
                                            Developments” means inventions, or claims to inventions, which constitute advancements,
                                            developments or improvements, whether or not patentable and whether or not the subject of
                                            any patent application, which are not sufficiently supported by the specification of a previously-filed
                                            patent or patent application within the Patent Rights to be entitled to the priority date
                                            of the previously-filed patent or patent application.

 

		2.12	“Patent
                                            Rights” means the Valid Claims of Licensed Patents to the extent assigned to or otherwise
                                            obtained by LLNS. This definition of Patent Rights excludes any rights in and to New Developments.

 

		2.13	“Related
                                            Party” means a corporation, firm or other entity with which, or individual with whom,
                                            LICENSEE and or any sublicensee (or any of their respective stockholders, subsidiaries or
                                            Affiliates) have an agreement, understanding, or arrangement (for example, but not by way
                                            of limitation, an option to purchase stock or other equity interest, or an arrangement involving
                                            a division of revenue, profits, special discounts, rebates, or allowances) unrelated to the
                                            Sale or exploitation of the Licensed Products or Licensed Services without which such other
                                            agreement, understanding, or arrangement, the amounts, if any, charged by LICENSEE or sublicensee
                                            to such entity or individual for the Licensed Product or Licensed Service would be higher
                                            than the Net Invoice Price actually received, or if such agreement, understanding, or arrangement
                                            results in LICENSEE or sublicensee extending to such entity or individual lower prices for
                                            such Licensed Product or Licensed Service than those charged to others without such agreement,
                                            understanding, or arrangement buying similar products or services in similar quantities.

 

    
	15GM0520	5	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		2.14	“Relationship-Influenced
                                            Sale” means a Sale of a Licensed Product, or any exploitation of the Licensed Product
                                            or Licensed Method, by LICENSEE and/or any sublicensee to (i) an Affiliate; (ii) a
                                            Joint Venture; or (iii) a Related Party.

 

		2.15	“Relationship-Influenced Sale
                                            Purchaser” means the purchaser of Licensed Product or Licensed Service in a Relationship-Influenced
                                            Sale.

 

		2.16	“Sale”
                                            means the act of selling, leasing or otherwise transferring, providing, or furnishing for
                                            use for any consideration. Correspondingly, “Sell” means to make or cause to
                                            be made a Sale, and “Sold” means to have made or caused to be made a Sale.

 

		2.17	“Valid
                                            Claim” means a claim of a patent or patent application in any country that (i) has
                                            not expired; (ii) has not been disclaimed; (iii) has not been cancelled or superseded,
                                            or if cancelled or superseded, has been reinstated; and (iv) has not been revoked, held
                                            invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent authority
                                            of competent jurisdiction over such claim in such country from which no further appeal has
                                            or may be taken.

 

		3.	LICENSE GRANT

 

		3.1	The license
                                            rights granted to LICENSEE by LLNS are set forth in Exhibit B (RIGHTS GRANTED AND PERFORMANCE
                                            OBLIGATIONS).

 

		3.2	The license
                                            granted hereunder will be subject to the overriding obligations to the U.S. Government including
                                            those set forth in 35 U.S.C. §§ 200-212 and applicable governmental implementing
                                            regulations and the obligation to report on utilization of the Invention set forth in 37
                                            CFR § 401.14(h).

 

		3.3	Nothing
                                            in this Agreement will be deemed to limit the right of LLNS to publish any and all technical
                                            data resulting from any research performed by LLNS relating to the Invention and to make,
                                            use or practice the Invention, Licensed Product, Licensed Service, Licensed Method, and associated
                                            technology, and allow other educational and non-profit institutions to do so for educational
                                            and research purposes.

 

		4.	SUBLICENSING RIGHTS AND OBLIGATIONS

 

		4.1	The sublicensing
                                            rights granted to LICENSEE by LLNS are set forth in Exhibit B (RIGHTS GRANTED
                                            AND PERFORMANCE OBLIGATIONS), Paragraph B.2 (Sublicensing Rights).

 

    
	15GM0520	6	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		4.2	LICENSEE must include in any
                                            sublicense all the rights and obligations due LLNS and the U.S. Government set forth in this
                                            Agreement.

 

		4.3	LICENSEE
                                            must require sublicensees to provide it with copies of all progress reports and royalty
                                            reports in accordance with the provisions of this Agreement, and LICENSEE will collect
                                            and deliver to LLNS all such reports due from sublicensees.

 

		4.4	LICENSEE
                                            must include in all sublicenses the notice that upon termination of this Agreement for
                                            any reason, LLNS, at its sole discretion, will determine whether any or all sublicenses will
                                            be canceled or assigned to LLNS.

 

		4.5	LICENSEE
                                            will notify LLNS of each sublicense granted hereunder and provide LLNS with a complete
                                            copy of each executed sublicense within thirty (30) days of issuance of the sublicense.

 

		4.6	For the
                                            purposes of this Agreement, the operations of all sublicensees shall be deemed to be the
                                            operations of LICENSEE, for which LICENSEE shall be responsible.

 

		4.7	Consideration
                                            owed to LLNS will be paid to LLNS on or before the due date of the royalty report applicable
                                            to the quarter in which consideration was due and owing to LICENSEE under the sublicense.
                                            LICENSEE will collect from the sublicensees and will pay to LLNS all fees, royalties,
                                            and the cash equivalent of any consideration due LLNS.

 

		5.	FEES, ROYALTIES, AND PAYMENTS

 

		5.1	Fees and
                                            royalties due on Net Sales of Licensed Products or Licensed Services will be as specified
                                            in this Article 5, Exhibit C (FEES AND ROYALTIES), and Article 7 (ROYALTY
                                            AND PROGRESS REPORTS) of this Agreement.

 

		5.2	As partial
                                            consideration for the rights granted to LICENSEE, LICENSEE and sublicensees
                                            will pay to LLNS a license issue fee as set forth in Exhibit C.

 

		5.3	As partial consideration for the rights
                                            granted to LICENSEE, LICENSEE will pay to LLNS a U.S. patent maintenance fee
                                            as set forth in Exhibit C.

 

		5.4	As partial
                                            consideration for all the rights granted to LICENSEE, LICENSEE and sublicensees
                                            will pay LLNS minimum annual royalties as set forth in Exhibit C.

 

    
	15GM0520	7	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		5.5	As partial
                                            consideration for all the rights granted to LICENSEE, LICENSEE and sublicensees
                                            will pay to LLNS earned royalties at the rate set forth in Exhibit C.

 

		5.6	Earned
                                            royalties shall accrue when Licensed Products or Licensed Services are invoiced, or if not
                                            invoiced, when delivered in a manner constituting a Net Sale as defined in Article 2
                                            (DEFINITIONS), Paragraph 2.10.

 

		5.7	Payment
                                            for earned royalties will include all royalties accrued up to the last day of the most recently
                                            completed calendar quarter on the dates specified below:

 

February 28 for the calendar quarter ending December 31;

 

May 31 for the calendar quarter ending March 31;

 

August 31 for the calendar quarter ending June 30;
and

 

November 30 for the calendar quarter ending September 30.

 

		5.8	All consideration
                                            due LLNS shall be payable in United States dollars. When Licensed Products or Licensed Services
                                            are sold for monies other than United States dollars, earned royalties will first be determined
                                            in the foreign currency of the country in which such Licensed Products or Licensed Services
                                            were Sold and then converted into equivalent United States dollars. The exchange rate will
                                            be the average exchange rate quoted in The Wall Street Journal during the last thirty (30)
                                            days of the reporting period.

 

		5.9	Earned
                                            royalties on Sales of Licensed Products or Licensed Services occurring in any country outside
                                            the United States shall not be reduced by any taxes, fees, or other charges imposed by the
                                            government of such country except those taxes, fees, and charges allowed under the provisions
                                            of Paragraph 2.10 (Net Sales). LICENSEE also will be responsible for all bank
                                            transfer charges.

 

		5.10	Notwithstanding
                                            the provisions of Article 26 (FORCE MAJEURE), if at any time legal restrictions prevent
                                            prompt remittance of any earned royalties or other consideration owed to LLNS by LICENSEE
                                            with respect to any country where a sublicense is issued or a Licensed Product or Licensed
                                            Service is Sold, then LICENSEE will convert the amount owed to LLNS into United States dollars
                                            and will pay LLNS directly from another source of funds in order to remit the entire amount
                                            owed to LLNS.

 

    
	15GM0520	8	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		5.11	No earned
                                            royalties will be collected or paid hereunder to LLNS on Licensed Products or Licensed Services
                                            Sold to the account of the U.S. Government. LICENSEE and its sublicensee will reduce
                                            the amount charged for Licensed Products or Licensed Services Sold to the U.S. Government
                                            by an amount equal to the royalty for such Licensed Products or Licensed Services otherwise
                                            due LLNS. LICENSEE will provide LLNS with U.S. Government contract numbers and a written
                                            statement by LICENSEE’s contracting officer that Sale of Licensed Products to
                                            the U.S. Government were reduced by the amount of royalty due LLNS.

 

		5.12	If LLNS
                                            must pursue legal means to obtain payments owed by LICENSEE, LICENSEE will
                                            pay LLNS for all legal costs and any other related costs expended by LLNS to collect payments
                                            owed by LICENSEE.

 

		5.13	In the
                                            event that any patent or any claim thereof included within the Patent Rights is held invalid
                                            in a final decision by a court of competent jurisdiction and last resort and from which no
                                            appeal has or can be taken, all obligation to pay royalties based on such patent or claim
                                            or any claim patentably indistinct therefrom will cease as of the date of such final decision.
                                            LICENSEE will not, however, be relieved from paying any royalties that accrued before
                                            such final decision and LICENSEE will be obligated to pay the full amount of royalties
                                            due hereunder to the extent that LLNS licenses one or more Valid Claims within the Patent
                                            Rights to LICENSEE with respect to Licensed Products or Licensed Services.

 

		6.	DUE DILIGENCE

 

		6.1	LICENSEE,
                                            upon execution of this Agreement, will diligently proceed with the development, manufacture,
                                            and Sale of Licensed Products and Licensed Services and use of Licensed Methods, and will
                                            earnestly and diligently market the same after execution of this Agreement and in quantities
                                            sufficient to meet the market demands thereof.

 

		6.2	LICENSEE
                                            will meet the specific performance obligations and milestones specified in Exhibit B
                                            (RIGHTS GRANTED AND PERFORMANCE OBLIGATIONS). If LICENSEE is unable to meet such milestones,
                                            LLNS will have the right and option to:

 

		(a)	convert the limited exclusive
                                            license for Licensed Patents to a nonexclusive license;

 

		(b)	negotiate
                                            with LICENSEE a new schedule and conditions for continuation of a limited exclusive
                                            license; or (c) terminate this Agreement per Article 10 (TERMINATION), Paragraph 10.1
                                            (Termination by LLNS).

 

    
	15GM0520	9	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		6.3	LICENSEE
                                            will comply with all governmental laws and obtain all necessary governmental approvals
                                            in each country where Licensed Products or Licensed Services are manufactured, used, Sold,
                                            imported, or offered for Sale.

 

		6.4	LLNS will
                                            notify LICENSEE if LLNS is approached by a third party seeking a license to make,
                                            use, or sell Licensed Products in LICENSEE’s Field of Use because commercial
                                            demand is not then being met. LICENSEE will negotiate in good faith with that third
                                            party to grant a sublicense for any Licensed Patents in the market for which LICENSEE
                                            and existing sublicensees are not meeting commercial demand. The determination to grant
                                            a sublicense may be based on LICENSEE’s business interests. LICENSEE
                                            will provide LLNS with justification for denying any such sublicense.

 

		6.5	During
                                            the term of this Agreement, LICENSEE will conduct normal, continuous business operations.
                                            If LICENSEE seeks protection under any United States bankruptcy proceedings during
                                            the term of this Agreement, LICENSEE will notify LLNS in writing no later than seventy-two
                                            (72) hours after the bankruptcy filing. Upon filing bankruptcy, the license automatically
                                            terminates as stated in Article 9 (LIFE OF THE AGREEMENT), Paragraph 9.2.

 

		6.6	To exercise
                                            either the right to terminate this Agreement or to reduce the exclusive licenses granted
                                            to LICENSEE to nonexclusive licenses for lack of diligence required in this Article 6,
                                            LLNS will give LICENSEE written notice of the deficiency. LICENSEE thereafter
                                            has thirty (30) days to cure the deficiency. If LLNS has not received written tangible evidence
                                            satisfactory to LLNS that the deficiency has been cured by the end of the thirty (30) day
                                            period, then LLNS may, at its option, terminate this Agreement immediately without the obligation
                                            to provide thirty (30) days notice as set forth in Paragraph 10.1 or reduce the exclusive
                                            licenses granted to LICENSEE to nonexclusive licenses by giving written notice to
                                            LICENSEE.

 

		7.	ROYALTY AND PROGRESS REPORTS

 

		7.1	LICENSEE
                                            will submit to LLNS a semi-annual progress report as described in Paragraph 7.2
                                            below covering activities by LICENSEE and its sublicensees related to the development
                                            and testing of all Licensed Products and Licensed Services. After the first Sale of Licensed
                                            Product or Licensed Service, LICENSEE is required to submit a progress report annually
                                            rather than semi-annually. Such progress report will be signed by LICENSEE’s
                                            President or his/her designee attesting to the accuracy of the information in the report.
                                            If LICENSEE fails to submit a timely progress report to LLNS, LLNS will be entitled
                                            to terminate this Agreement. If either party terminates this Agreement before any Licensed
                                            Products or Licensed Services are Sold or before this Agreement’s expiration, a final
                                            progress report covering the period prior to termination must be submitted within thirty
                                            (30) days of termination.

 

    
	15GM0520	10	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		7.2	The progress
                                            reports submitted under Paragraph 7.1 above will include, but not be limited to, a reasonably
                                            detailed summary of the following topics:

 

		•	Summary of work completed toward commercialization of Licensed
                                            Patents;

 

		•	Schedule of anticipated events or
                                            milestones, including status of those events or milestones. Should LICENSEE wish to
                                            change the schedule of events or milestones specified in Exhibit B (RIGHTS GRANTED AND
                                            PERFORMANCE OBLIGATIONS), LICENSEE must request advance written approval from LLNS;

 

		•	A financial statement showing the investments made in the commercialization
                                            effort to date;

 

		•	Anticipated and actual market introduction dates of each Licensed
                                            Product or Licensed Service;

 

		•	Summary of marketing and sales activities, including copies of
                                            marketing and sales literature; and

 

		•	activities of the sublicensees, if any.

 

		7.3	LICENSEE also will report to
                                            LLNS the date of first Sale or other exploitation of a Licensed Product or Licensed Service
                                            within thirty (30) days of such Sale.

 

		7.4	After
                                            the first Sale or other exploitation of a Licensed Product or Licensed Service, LICENSEE
                                            will provide quarterly royalty reports and payments to LLNS on or before each February 28,
                                            May 31, August 31, and November 30 of each year. If there were no Sale of
                                            Licensed Products or Licensed Services, the report will state that. Royalty reports will
                                            be signed by LICENSEE’s President or Chief Financial Officer, or their designee,
                                            attesting to the accuracy of the report. Each such royalty report will cover the most recently
                                            completed calendar quarter (October through December, January through March, April through
                                            June, and July through September) and will show:

 

		7.4.1	the
                                            gross invoice prices and Net Sales of Licensed Products or Licensed Services Sold or otherwise
                                            exploited by LICENSEE and its sublicensees during the most recently completed calendar
                                            quarter;

 

    
	15GM0520	11	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		7.4.2	the
                                            number of Licensed Products or Licensed Services Sold or otherwise exploited by LICENSEE
                                            and its sublicensees during the most recently completed calendar quarter;

 

		7.4.3	the place of manufacture of
                                            Licensed Products or practice of Licensed Services;

 

		7.4.4	the royalties, in U.S. dollars,
                                            payable hereunder with respect to Net Sales;

 

		7.4.5	the method used to calculate
                                            the royalty, specifying all deductions taken and the dollar amount of each such deduction;
                                            and

 

		7.4.6	the exchange rates used, if
                                            any.

 

		7.5	LICENSEE
                                            will provide LLNS, within sixty (60) days after the end of each calendar year, with an
                                            annual statement of royalty accounts attested to by LICENSEE’s President, or
                                            Chief Financial Officer, or their designee as being accurate. LLNS will protect such statements
                                            as Proprietary Information and not disseminate them unless required by law.

 

		8.	BOOKS AND RECORDS

 

		8.1	LICENSEE
                                            will keep books and records accurately showing all payments due LLNS and all Licensed
                                            Products and Licensed Services manufactured (including place of manufacture), used, offered
                                            for Sale, imported, and/or Sold under the terms of this Agreement. Such books and records
                                            will be preserved for at least five (5) years after the date of the payment to which
                                            they pertain and will be open to inspection by representatives or agents of LLNS at reasonable
                                            times to determine their accuracy and assess LICENSEE’s compliance with the
                                            terms of this Agreement.

 

		8.2	The fees
                                            and expenses of representatives of LLNS performing such an examination will be borne by LLNS.
                                            If, however, an error in royalties of more than five percent (5%) of the total royalties
                                            due for any year is discovered, LICENSEE will bear the cost of the examination and
                                            will remit such underpayment to LLNS within thirty (30) days of the examination result.

 

		8.3	LICENSEE
                                            will provide LLNS with an annual financial statement of LICENSEE, including at
                                            a minimum a balance sheet and operating statement attested to by LICENSEE’s
                                            President, or Chief Financial Officer, or their designee as being accurate or LICENSEE’s
                                            annual report. Such statement will be due to LLNS within one hundred twenty (120) days following
                                            the close of LICENSEE’s fiscal year to which such statement relates.

 

    
	15GM0520	12	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		9.	LIFE
                                            OF THE AGREEMENT

 

		9.1	Unless
                                            otherwise terminated by operation of law, Paragraph 9.2, or by acts of the Parties in
                                            accordance with the terms of this Agreement, this Agreement will remain in effect from the
                                            Effective Date until the expiration or abandonment of the last of the Patent Rights licensed
                                            hereunder.

 

		9.2	This
                                            Agreement will automatically terminate upon the filing of a petition for relief under the
                                            United States Bankruptcy Code by or against LICENSEE as a debtor or alleged debtor.

 

		9.3	Any
                                            termination of this Agreement will not affect the rights and obligations set forth in the
                                            following Articles: Article 2 (DEFINITIONS), Article 5 (FEES, ROYALTIES, AND PAYMENTS),
                                            Article 8 (BOOKS AND RECORDS), Article 9 (LIFE OF THE AGREEMENT), Article 11
                                            (DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION), Article 14 (USE OF NAMES
                                            AND TRADEMARKS), Article 15 (LIMITED WARRANTY), Article 16 (INDEMNIFICATION), Article 17
                                            (INSURANCE), Article 21 (NOTICES), Article 22 (GOVERNING LAWS; VENUE; ATTORNEYS’
                                            FEES), and Article 28 (PROPRIETARY INFORMATION).

 

		9.4	The
                                            termination or expiration of this Agreement will not relieve LICENSEE of its obligation
                                            to pay any fees, royalties, and reimbursements for foreign filing costs, or other payments
                                            owed to LLNS at the time of such termination or expiration and will not impair any accrued
                                            right of LLNS.

 

		10.	TERMINATION

 

		10.1	Termination
                                            by LLNS: If LICENSEE fails to perform any material term or covenant of this Agreement,
                                            LLNS may give written notice to LICENSEE that if LICENSEE has not cured such
                                            failure within thirty (30) days after the effective date of receipt of the notice, this Agreement
                                            will terminate at the end of such thirty (30) day period or at the end of such longer period
                                            as may be set forth in LLNS’s notice.

 

		10.2	Termination
                                            by LICENSEE: LICENSEE will have the right at any time to terminate this Agreement
                                            by providing a Notice of Termination to LLNS and paying any outstanding fees owed LLNS. Termination
                                            of this Agreement will be effective sixty (60) days after the date such notice takes effect.

 

    
	15GM0520	13	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		10.3	This
                                            Agreement will terminate effective ten (10) days after the effective date of notice
                                            by LLNS if LICENSEE ceases to carry on its business.

 

		11.	DISPOSITION
                                            OF LICENSED PRODUCTS ON HAND UPON TERMINATION

 

		11.1	Upon
                                            termination of this Agreement, LICENSEE may Sell all previously made or partially
                                            made Licensed Products, but no additional Licensed Products, within a period of sixty (60)
                                            days after the date of termination, provided, however, that the Sale of such Licensed Products
                                            will be subject to the terms of this Agreement including, but not limited to, the payment
                                            of earned royalties at the rates and at the times provided herein and the rendering of reports
                                            in connection therewith.

 

		11.2	Within
                                            thirty (30) days after termination of this Agreement by either Party, LICENSEE will
                                            provide LLNS with a written inventory of all Licensed Products in process of manufacture
                                            or in stock on the date of termination. LICENSEE may complete Licensed Products in
                                            the process of manufacture at the time of termination, and may dispose of Licensed Products
                                            for sixty (60) days after the date of termination provided that LICENSEE pays royalties
                                            to LLNS on such dispositions. At the conclusion of the sixty (60) day period, LICENSEE
                                            will destroy any remaining Licensed Products in stock or in process of manufacture and
                                            certify such destruction to LLNS.

 

		11.3	LICENSEE
                                            may not practice Licensed Methods after the date of termination of this Agreement except
                                            as necessary to complete the manufacture of Licensed Products as permitted under Paragraph 11.2.

 

		12.	PATENT
                                            PROSECUTION AND MAINTENANCE

 

		12.1	LLNS
                                            will prosecute U.S. patent applications and maintain U.S. patents licensed under this Agreement
                                            at LLNS’s expense, except LICENSEE will pay all of the expenses associated with
                                            patent interferences, patent appeals to the USPTO Board of Appeals, patent appeals to a Federal
                                            Court, patent re-examinations, patent re-issues, and trademark oppositions and/or cancellations.
                                            LICENSEE agrees to pay all patent prosecution costs that arise out of future inventions
                                            generated under a Cooperative Research and Development Agreement (CRADA) or Work for Others
                                            (WFO) agreement. For avoidance of doubt, LICENSEE will not be responsible for any
                                            of the foregoing expenses that were incurred prior to the Effective Date.

 

    
	15GM0520	14	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		13.	PATENT
                                            INFRINGEMENT

 

		13.1	In
                                            the event that LLNS (to the extent of the actual knowledge of the licensing professional
                                            responsible for the administration of this Agreement) or LICENSEE learns of infringement
                                            of potential commercial significance of any patent licensed under this Agreement, the knowledgeable
                                            party will provide the other (i) with written notice of such infringement and (ii) with
                                            any evidence of such infringement available to it (the “Infringement Notice”).
                                            Following such notification, the Parties will confer. During the period in which, and in
                                            the jurisdiction where, LICENSEE has exclusive rights under this Agreement, neither
                                            LLNS nor LICENSEE will notify a third party (including the infringer) of infringement
                                            or put such third party on notice of the existence of any Patent Rights without first obtaining
                                            consent of the other. LLNS shall have the right to terminate this Agreement immediately without
                                            the obligation to provide 60 days’ notice as set forth in Paragraph 10.1 if LICENSEE
                                            notifies a third party of infringement or puts such third party on notice of the existence
                                            of any Patent Rights with respect to such infringement without first obtaining the written
                                            consent of LLNS. Both LLNS and LICENSEE will use their diligent efforts to cooperate
                                            with each other to terminate such infringement without litigation.

 

		13.2	If
                                            infringing activity of potential commercial significance by the infringer has not been abated
                                            within ninety (90) days following the date the Infringement Notice takes effect, LICENSEE
                                            will have first right, but not the obligation, to bring an infringement action for Licensed
                                            Patents at its own expense, in its own name, and entirely under its own direction and control.
                                            At LICENSEE’s request and at LLNS’s discretion, LLNS will reasonably assist
                                            LICENSEE at LICENSEE’s expense in such actions or proceedings, and will
                                            lend its name to, or join such actions or proceedings if required by law in order for LICENSEE
                                            to bring such action. LLNS may voluntarily join such suit at its own expense, but may
                                            not thereafter commence suit against the infringer for the acts of infringement that are
                                            the subject of LICENSEE’s suit or any judgment rendered in that suit. LICENSEE
                                            may not join LLNS in a suit initiated by LICENSEE without LLNS’s prior written
                                            consent. If, in a suit initiated by LICENSEE, LLNS is involuntarily joined other than
                                            by LICENSEE, LICENSEE will pay any costs incurred by LLNS arising out of such
                                            suit, including but not limited to, any legal fees of counsel that LLNS selects and retains
                                            to represent it in the suit.

 

		13.3	If,
                                            within a hundred and twenty (120) days following the date the Infringement Notice takes effect,
                                            infringing activity of potential commercial significance by the infringer has not been abated
                                            and if LICENSEE has not brought suit against the infringer, LLNS may institute suit
                                            for patent infringement against the infringer. If LLNS institutes such suit, LICENSEE
                                            may not join such suit without LLNS’s consent and may not thereafter commence suit
                                            against the infringer for the acts of infringement that are the subject of LLNS’s suit
                                            or any judgment rendered in that suit.

 

    
	15GM0520	15	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		13.4	Any
                                            recovery or settlement received in connection with any suit will first be shared by LLNS
                                            and LICENSEE equally to cover the litigation costs each incurred, and next shall be
                                            paid to LLNS or LICENSEE to cover any litigation costs it incurred in excess of the
                                            litigation costs of the other. In any suit initiated by LICENSEE, any recovery in
                                            excess of litigation costs will be shared between LICENSEE and LLNS as follows: (a) for
                                            any recovery other than amounts paid for willful infringement: (i) LLNS will receive
                                            fifteen percent (15%) of the recovery if LLNS was not a party in the litigation and did not
                                            incur any litigation costs, (ii) LLNS will receive twenty-five percent (25%) of the
                                            recovery if LLNS was a party in the litigation, but did not incur any litigation costs, including
                                            the provisions of Paragraph 13.2 above, and (iii) LLNS will receive fifty percent
                                            (50%) of the recovery if LLNS incurred any litigation costs in connection with the litigation;
                                            and (b) for any recovery for willful infringement, LLNS will receive fifty percent (50%)
                                            of the recovery. In any suit initiated by LLNS, any recovery in excess of litigation costs
                                            will belong to LLNS. LLNS and LICENSEE agree to be bound by all determinations of
                                            patent infringement, validity, and enforceability (but no other issue) resolved by any adjudicated
                                            judgment in a suit brought in compliance with this Article 13.

 

		13.5	Any
                                            agreement made by LICENSEE for purposes of settling litigation or other dispute shall
                                            comply with the requirements of Article 4 (SUBLICENSING RIGHTS AND OBLIGATIONS) of this
                                            Agreement.

 

		13.6	Each
                                            party will cooperate with the other in litigation proceedings instituted hereunder but at
                                            the expense of the party who initiated the suit (unless such suit is being jointly prosecuted
                                            by the parties).

 

		13.7	Any
                                            litigation proceedings will be controlled by the party bringing the suit, except that LLNS
                                            may be represented by counsel of its choice in any suit brought by LICENSEE.

 

		14.	USE
                                            OF NAMES AND TRADEMARKS

 

Nothing contained in this Agreement will be construed
as conferring any right to either Party to use in advertising, publicity, or other promotional activities any name, trade name, trademark,
or other designation of the other Party (including a contraction, abbreviation or simulation of any of the foregoing). Unless consented
to in writing by LLNS, the use by LICENSEE of the name “Lawrence Livermore National Laboratory” or “Lawrence Livermore
National Security, LLC” in advertising, publicity, or other promotional activities is expressly prohibited.

 

    
	15GM0520	16	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		15.	LIMITED
                                            WARRANTY

 

		15.1	LLNS
                                            warrants to LICENSEE that it has the lawful right to grant this license.

 

		15.2	Except
                                            as expressly set forth in this Agreement, the licenses and the associated Invention, Patent
                                            Rights, Licensed Products, Licensed Services, and Licensed Methods are provided by LLNS WITHOUT
                                            WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF
                                            ANY KIND, EITHER EXPRESS OR IMPLIED. LLNS MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY
                                            THAT THE INVENTION, PATENT RIGHTS, LICENSED PRODUCTS, OR LICENSED METHODS WILL NOT INFRINGE
                                            ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS.

 

		15.3	Nothing
                                            in this Agreement is or will be construed as:

 

		15.3.1	a
                                            warranty or representation by LLNS as to the validity, enforceability, or scope of any Patent
                                            Rights; or

 

		15.3.2	a
                                            warranty or representation that anything made, used, sold, or otherwise disposed of under
                                            any license granted in this Agreement is or will be free from infringement of patents, copyrights,
                                            or other rights of third parties; or

 

		15.3.3	an
                                            obligation to bring or prosecute actions or suits against third parties for patent infringement
                                            except as provided in Article 13 (PATENT INFRINGEMENT); or

 

		15.3.4	conferring
                                            by implication, estoppel, or otherwise any license or rights under any patents or other rights
                                            of LLNS other than Patent Rights, regardless of whether such patents are dominant or subordinate
                                            to Patent Rights; or

 

		15.3.5	an
                                            obligation to furnish any New Developments, know-how, technology, or technological information
                                            not provided in Patent Rights.

 

		15.4	LIMITATION
                                            OF LIABILITY - LLNS OR DOE WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE
                                            GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT,
                                            OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED
                                            BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS
                                            AGREEMENT, FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT
                                            LIABILITY AND BREACH OF WARRANTY) EVEN IF LLNS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
                                            DAMAGES.

 

    
	15GM0520	17	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		16.	INDEMNIFICATION

 

LICENSEE will, and will require its sublicensees
to, indemnify, hold harmless, and defend LLNS, DOE, their officers, employees, and agents; the sponsors of the research that led to the
Invention; and the inventors of any invention claimed in the patent under Patent Rights (including the Licensed Products, Licensed Services,
and Licensed Methods contemplated thereunder) and their employers against any and all claims, suits, losses, damage, costs, fees, and
expenses resulting from, or arising out of, the exercise of this license. LICENSEE will pay any and all costs, including reasonable
attorneys’ fees, incurred by LLNS in enforcing this indemnification. This indemnification will include, but will not be limited
to, any product liability.

 

		17.	INSURANCE

 

		17.1	LICENSEE
                                            will insure its activities relating to this Agreement at its own cost with an insurance
                                            company acceptable to LLNS. LICENSEE will obtain, keep in force, and maintain insurance
                                            as follows with an insurance company acceptable to LLNS or an equivalent program of self-insurance:
                                            Comprehensive or Commercial Form General Liability Insurance, including contractual
                                            liability and product liability, with coverage as follows:

 

		17.1.1	Each
                                            occurrence coverage of not less than Five Million Dollars ($5,000,000); and

 

		17.1.2	Product
                                            Liability Insurance: Completed operations aggregate coverage of not less than Ten Million
                                            Dollars ($10,000,000); and

 

		17.1.3	Personal
                                            and Advertising Injury: Coverage of not less than Five Million Dollars ($5,000,000); and

 

		17.1.4	General
                                            Aggregate (Commercial Form only): Coverage of not less than Ten Million Dollars ($10,000,000).

 

    
	15GM0520	18	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		17.2	Prior
                                            to obtaining the appropriate government regulatory approvals, LICENSEE may obtain
                                            insurance coverage at lower levels, but the initial minimum levels must be as follows:

 

		17.2.1	Each
                                            occurrence coverage of not less than Five Hundred Thousand Dollars ($500,000); and

 

		17.2.2	Product
                                            Liability Insurance: Completed operations aggregate coverage of not less than One Million
                                            Dollars ($1,000,000); and

 

		17.2.3	Personal
                                            and Advertising Injury: Coverage of not less than Five Hundred Thousand Dollars ($500,000);
                                            and

 

		17.2.4	General
                                            Aggregate (Commercial Form only): Coverage of not less than One Million Dollars ($1,000,000).

 

		17.3	These
                                            coverages do not limit the liability of LICENSEE to LLNS in any way. LICENSEE
                                            will provide LLNS, upon request, with certificates of insurance or self-insurance, including
                                            renewals that show compliance with these requirements. LICENSEE’s failure to
                                            maintain such required insurance will be considered a material breach of this Agreement.

 

		17.4	If
                                            the required insurance is written on a claims-made form, coverage must provide a retroactive
                                            date of placement before or coinciding with the Effective Date of this Agreement.

 

		17.5	LICENSEE
                                            will maintain the general liability insurance specified in this Article 17 during
                                            the period that the Licensed Patents of LLNS are being used and/or Licensed Products are
                                            being Sold or otherwise commercially distributed by LICENSEE, and for a period of
                                            not less than three (3) years thereafter.

 

		17.6	LICENSEE’s
                                            insurance coverage must:

 

		17.6.1	Provide
                                            for at least thirty (30) days advance written notice to LLNS of cancellation or any modification;
                                            and

 

		17.6.2	Indicate
                                            that DOE, LLNS, and their respective officers, employees, students, and agents, are endorsed
                                            on the policy as additional insureds; and

 

    
	15GM0520	19	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		17.6.3	Include
                                            a provision that the coverage is primary and does not participate with or is in excess of
                                            any valid and collectible insurance, program, or self-insurance carried or maintained by
                                            LLNS.

 

		18.	WAIVER

 

		18.1	No
                                            provision of this Agreement is deemed waived and no breach excused unless such waiver or
                                            consent is made in writing and signed by the waiving or consenting Party.

 

		18.2	Failure
                                            on the part of either Party to exercise or enforce any right of such Party under this Agreement
                                            will not be a waiver by such Party of any right, or operate to bar the enforcement or exercise
                                            of the right at any time thereafter.

 

		19.	ASSIGNABILITY

 

This Agreement is binding on and inures
to the benefit of LLNS, its successors and assigns, but is personal to LICENSEE. Any assignment of this Agreement for any reason
including but not limited to merger or sale of majority assets is at the sole discretion of LLNS and requires prior written consent of
LLNS. LICENSEE will pay LLNS an Assignment Fee as set forth in Exhibit C (FEES AND ROYALTIES) prior to such assignment being
executed by LLNS.

 

		20.	LATE
                                            PAYMENTS

 

In the event that royalty payments, fees, or
other monies owed to LLNS are not received by LLNS when due, LICENSEE will pay to LLNS interest at a rate of ten percent (10%)
simple interest per annum. Such interest will be calculated from the date payment was due until actually received by LLNS. Such accrual
of interest will be in addition to, and not in lieu of, enforcement of any other rights of LLNS due to such late payment. LICENSEE
will pay any costs incurred by LLNS in collecting late payments.

 

		21.	NOTICES

 

		21.1	Any
                                            notice or payment required to be given to either Party will be deemed to have been properly
                                            given and to be effective:

 

		21.1.1	on
                                            the date of delivery if delivered in person; or

 

		21.1.2	on
                                            the date of mailing if mailed by first-class certified mail, postage paid; or

 

		21.1.3	on
                                            the date of mailing if mailed by any global express carrier service that requires the recipient
                                            to sign the documents demonstrating the delivery of such notice of payment;

 

    
	15GM0520	20	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

to the respective addresses given below,
or to another address as designated in writing by the Party changing its address.

 

	In the case of LICENSEE:	 	BIONOMICS DIAGNOSTICS
	 	 	[Redacted
                                            – Address]

	 	 	[Redacted
                                            – Address]

	 	 	Attention: Director
	 	 	Phone: [Redacted]

 

	In
    the case of LLNS:	 	 
	 	 	 
	All correspondence,
    original progress reports, and royalty reports:	 	 
	 	 	Lawrence
    Livermore National Laboratory
	 	 	Industrial
    Partnerships Office
	 	 	P.O. Box
    808, L-795
	 	 	7000 East
    Avenue, L-795
	 	 	Livermore,
    CA 94550
	 	 	Attention:
    Director, Industrial Partnerships
	 	 	Fax: (925)
    423-8988

 

	Payments and copies of corresponding
    royalty reports:	 	Lawrence Livermore National Laboratory
	 	 	P.O. Box 5517
	 	 	Livermore, CA 94551

 

		22.	GOVERNING
                                            LAWS; VENUE; ATTORNEYS FEES

 

		22.1	The
                                            Parties will attempt to jointly and promptly resolve any disputes arising from this Agreement.
                                            If the Parties are unable to resolve a dispute within a reasonable time from one Party’s
                                            written notice to the other that dispute resolution has begun, then either Party may commence
                                            proceedings in a court of competent jurisdiction.

 

		22.2	THIS
                                            AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA,
                                            excluding any choice of law rules that would direct the application of the laws of another
                                            jurisdiction, but the scope and validity of any patent or patent application will be governed
                                            by the applicable laws of the country of such patent or patent application. Any legal action
                                            related to this Agreement will be conducted in the State of California.

 

		23.	PATENT
                                            MARKING

 

LICENSEE will mark all Licensed
Products and their containers that are made, used, Sold, or otherwise disposed of under this Agreement in accordance with applicable
patent marking laws.

 

    
	15GM0520	21	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		24.	GOVERNMENT
                                            APPROVAL OR REGISTRATION

 

If this Agreement or any associated
transaction is required by the law of any nation to be either approved, permitted, or registered with any governmental agency, LICENSEE
will assume all legal obligations to do so. LICENSEE will notify LLNS if LICENSEE becomes aware that this Agreement
is subject to a United States or foreign government reporting, permitting, or approval requirement. LICENSEE will make all necessary
filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting, permitting, or
approval process.

 

		25.	COMPLIANCE
                                            WITH LAWS

 

		25.1	LICENSEE
                                            will comply with all applicable international, national, state, regional and local laws
                                            and regulations in performing its obligations hereunder and in its use, manufacture, Sale,
                                            or import of the Licensed Products, Licensed Services, or practice of the Licensed Method.

 

		25.2	LICENSEE
                                            will comply with all applicable United States and foreign laws with respect to the transfer
                                            of Licensed Products and related technical data and the provision of Licensed Services to
                                            foreign countries, including, without limitation, the International Traffic in Arms Regulations
                                            (ITAR) and the Export Administration Regulations (EAR).

 

		25.3	LICENSEE
                                            will manufacture Licensed Products and practice the Licensed Method in compliance with
                                            applicable government importation laws and regulations of a particular country for Licensed
                                            Products made outside the particular country in which such Licensed Products are used or
                                            Sold.

 

		26.	FORCE
                                            MAJEURE

 

		26.1	Except
                                            for LICENSEE’s obligation to make any payments to LLNS hereunder, the Parties
                                            will not be responsible for any failure to perform due to the occurrence of any events beyond
                                            their reasonable control which render their performance impossible or onerous, including,
                                            but not limited to: accidents (environmental, toxic spill, etc.); acts of God; biological
                                            or nuclear incidents; casualties; earthquakes; fires; floods; governmental acts, orders or
                                            restrictions; inability to obtain suitable and sufficient labor, transportation, fuel and
                                            materials; local, national, or state emergency; power failure and power outages; acts of
                                            terrorism; strike; and war.

 

    
	15GM0520	22	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		26.2	Either
                                            Party to this Agreement, however, will have the right to terminate this Agreement upon thirty
                                            (30) days prior written notice if either Party is unable to fulfill its obligations under
                                            this Agreement due to any of the causes mentioned in Paragraph 26.1 for a period of
                                            one (1) year.

 

		27.	UNITED
                                            STATES PREFERENCE

 

LICENSEE agrees that any Licensed
Products embodying the Invention or produced through the use thereof will be manufactured substantially in the United States.

 

		28.	PROPRIETARY
                                            INFORMATION

 

LLNS may release to the inventors and
senior administrators employed by LLNS the terms of this Agreement upon their request. If such release is made, LLNS will give notice
of the proprietary nature of the terms and request that the recipient maintain the confidentiality. If a third party inquires whether
a license to Licensed Patents is available, LLNS may disclose the existence of this Agreement and the extent of the grant in Article 3
(LICENSE GRANT) to the third party, but will not disclose the name of LICENSEE or any other terms, except with LICENSEE’s
consent or as required under a government audit, the California Public Records Act, the Freedom of Information Act, or other applicable
law.

 

		29.	MISCELLANEOUS

 

		29.1	The
                                            headings of the several sections are inserted for convenience of reference only and are not
                                            intended to affect the meaning or interpretation of this Agreement.

 

		29.2	No
                                            amendment or modification of this Agreement will be valid or binding upon the Parties unless
                                            made in writing and signed on behalf of each Party.

 

		29.3	This
                                            Agreement with the attached Exhibits A, B, C, and D embodies the entire understanding
                                            of the Parties and supersedes all previous communications, representations, or understandings,
                                            whether oral or written, between the Parties relating to the subject matter hereof.

 

		29.4	If
                                            any of the provisions contained in this Agreement are held to be invalid, illegal, or unenforceable
                                            in any respect, such invalidity, illegality, or unenforceability will not affect any other
                                            provisions hereof, and this Agreement will be construed as if such invalid or illegal or
                                            unenforceable provisions had never been contained herein.

 

    
	15GM0520	23	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		29.5	No
                                            provisions of this Agreement are intended or will be construed to confer upon or give to
                                            any person or entity other than LLNS and LICENSEE any rights, remedies, or other benefits
                                            under, or by reason of, this Agreement.

 

		29.6	In
                                            performing their respective duties under this Agreement, each of the Parties will be operating
                                            as an independent contractor. Nothing contained herein will in any way constitute any association,
                                            partnership, or joint venture between the Parties hereto, or be construed to evidence the
                                            intention of the Parties to establish any such relationship. Neither Party will have the
                                            power to bind the other Party or incur obligations on the other Party’s behalf without
                                            the other Party’s prior written consent.

 

In witness whereof, both LLNS and LICENSEE
have executed this Agreement, in duplicate originals, by their respective officers hereunto duly authorized, on the date and year
hereinafter written.

 

	BIONOMICS
    DIAGNOSTICS	 	LAWRENCE LIVERMORE
    NATIONAL SECURITY, LLC LAWRENCE LIVERMORE NATI S NAL LABORATORY
	 	 	 
	By:	 	 	 	By:	 	 
	 	 	(Signature)	 	 	 	(Signature)
	 	 	 	 	 	 	 
	Name:	 	 	 	Name:	 	 
	 	 	 	 	 	 	 
	Title:	 	 	 	Title:	 	 
	 	 	 	 	 	 	 
	Date
    signed:	 	 	Date
    signed:	 

 

    
	15GM0520	24	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

Exhibit A
 – Licensed Patents

 

The Licensed Patents are as follows:

 

UNITED STATES PATENTS:

 

	Invention

    Disclosure 

    Number	Patent

    Number	Title	Inventors	Issue
    Date
	IL11778A	8,298,763	Automated
    High-Throughput Flow-Through Real-Time Diagnostic System	John
    Frederick Regan	10/30/12
	IL11901A	8,828,716	Disposable
    and Removable Nucleic Acid Extraction and Purification Cartridges for Automated Flow-Through Systems	John
    Frederick Regan	9/9/14

 

UNITED STATES PATENT APPLICATIONS:

 

	Invention

    Disclosure 

    Number	Patent

    Application 

    Number	Title	Inventors	Filing
    Date
	IL11778B	13/607,494	Automated
    High-Throughput Flow-Through Real-Time Diagnostic System	John
    Frederick Regan	9/7/12

 

    
	15GM0520	25	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

Exhibit B
- Rights Granted And Performance Obligations

 

NOTICE

 

LICENSEE considers information
in this Exhibit B to be Proprietary.

 

		B.1	Rights
                                            Granted

 

Subject to the limitations set forth
in this Agreement, LLNS hereby grants to LICENSEE an exclusive, non-transferable, royalty-bearing, license under Patent Rights to make
Licensed Products and offer Licensed Services in the United States and to use, Sell, offer for Sale, and import Licensed Products and
Licensed Services and to practice Licensed Methods in the Field of Use in the United States.

 

“Field of Use” means Environmental
Surveillance, Food Testing, and Human Clinical Diagnostics.

 

		B.2	Sublicensing
                                            Rights

 

LLNS also grants to LICENSEE, so long
as it retains exclusive rights in the Field of Use under this Agreement, the right to issue sublicenses to Affiliates, Joint Ventures,
and third parties (“sublicensees”) to make Licensed Products and offer Licensed Services in the United States and to use,
Sell, offer for Sale, and import Licensed Products and Licensed Services and to practice the Licensed Method in the United States. For
the avoidance of doubt, Affiliates and Joint Ventures shall have no licenses under the Patent Rights unless such Affiliates and Joint
Ventures are granted a sublicense.

 

		B.3	Rights
                                            Excluded

 

Rights that are not specifically granted
elsewhere in this Agreement are specifically excluded from the License.

 

		B.4	Future
                                            Rights

 

There are no future rights allocated
in this Agreement.

 

		B.5	Performance
                                            Obligations

 

		B.5.1	LICENSEE
                                            will complete proof-of-concept prototype by December 31, 2016.

 

    
	15GM0520	26	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		B.5.2	LICENSEE
                                            will complete commercial prototype by July 31, 2018.

 

		B.5.3	LICENSEE
                                            will complete submission for approval to perform food pathogen testing in the United
                                            States by September 31, 2018.

 

		B.5.4	LICENSEE
                                            will achieve clearance to perform food pathogen testing in the United States by September 31,
                                            2019.

 

		B.5.5	LICENSEE
                                            will achieve First Commercial Sale (“FCS”) in the United States by December 31,
                                            2020.

 

		B.5.6	LICENSEE
                                            will achieve gross cumulative sales revenues from the Sales of Licensed Products of at
                                            least Ten Million Dollars ($10,000,000) within the first three (3) years of achieving
                                            FCS.

 

		B.5.7	The
                                            sales requirements specified above may, by mutual written consent of LICENSEE and
                                            LLNS, be amended and/or extended at the written request of LICENSEE to LLNS, based
                                            upon legitimate business reasons specified in reasonable detail in such written request.

 

		B.5.8	The
                                            first progress report will be due on February 28, 2016.

 

		B.5.9	LICENSEE
                                            will diligently proceed to commercially develop, file relevant regulatory applications
                                            for, and attempt to obtain relevant regulatory commercialization approvals with respect to
                                            the manufacturing, marketing, and sale of Licensed Products.

 

    
	15GM0520	27	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

Exhibit C
- Fees And Royalties Notice

 

LICENSEE considers information
in this Exhibit C to be Proprietary.

 

		C.1	License
                                            Issue Fee

 

		C.1.1	As
                                            partial consideration for this Agreement, LICENSEE will pay to LLNS a non-refundable issue
                                            fee of Sixty Thousand Dollars ($60,000) (License Issue Fee) due on the Effective Date and
                                            payable as follows:

 

		C.1.1.1	Ten
                                            Thousand Dollars ($10,000) to be paid when LICENSEE executes the Agreement;

 

		C.1.1.2	Ten
                                            Thousand Dollars ($10,000) to be paid within five (5) months after the Effective Date;

 

		C.1.1.3	Twenty
                                            Thousand Dollars ($20,000) to be paid within six (6) months after the Effective Date;
                                            and

 

		C.1.1.4	Twenty
                                            Thousand Dollars ($20,000) to be paid within nine (9) months after the Effective Date.

 

		C.1.2	LLNS
                                            will execute the Agreement after receipt of LICENSEE’s executed copies of the
                                            Agreement and payment of the License Issue Fee.

 

		C.1.3	The
                                            License Issue Fee will not be credited against any other royalty or fee due from LICENSEE
                                            to LLNS.

 

		C.1.4	In
                                            the event that LICENSEE grants sublicenses, LICENSEE will collect an issue
                                            fee equal to or greater than the License Issue Fee. LICENSEE will pay to LLNS Fifty
                                            Percent (50%) of any issue fee from sublicensing.

 

		C.2	Earned
                                            Royalties

 

		C.2.1	In
                                            addition to the License Issue Fee, LICENSEE will pay LLNS an earned royalty of Three
                                            Percent (3%) on Net Sales. Payments of earned royalties will be in accordance with the requirements
                                            of Article 5 (FEES, ROYALTIES AND PAYMENTS) and Article 7 (ROYALTY AND PROGRESS
                                            REPORTS) of this Agreement

 

    
	15GM0520	28	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		C.2.2	Royalty
                                            Stacking Provision: If LICENSEE is required to enter into a royalty-bearing license
                                            under intellectual property rights owned by a third party in order to make, use, sell, offer
                                            for sale, or import Licensed Products in the Field of Use, LICENSEE may deduct from
                                            royalties due under this Agreement on such Licensed Products Fifty Percent (50%) of royalties
                                            actually paid by LICENSEE for the same reporting period to such third party, but in
                                            no event will the royalties paid to LLNS under this Agreement be less than Fifty Percent
                                            (50%) of the amount due pursuant to Paragraph C.2 hereof. This provision will apply
                                            only to earned royalties paid to third parties on the same basis as required by Paragraph C.2
                                            hereof, and no credit will be allowed for lump-sum license fees, for milestone payments,
                                            for minimum annual royalties in excess of accrued royalties, for any amounts paid for past
                                            infringement of any third party’s rights or for any amount paid for rights not required
                                            to permit LICENSEE to make, use, sell, offer for sale, and import Licensed Products
                                            as provided in this Agreement.

 

		C.2.3	In
                                            the event that LICENSEE grants sublicenses, LICENSEE will collect an earned
                                            royalty equal to or greater than the earned royalty paid by LICENSEE. LICENSEE
                                            will pay to LLNS Fifty Percent (50%) of earned royalties on Net Sales by any Sublicensee
                                            in accordance with Article 4 (SUBLICENSING RIGHTS AND OBLIGATIONS) and Article 7
                                            of this Agreement.

 

		C.3	U.S.
                                            Patent Maintenance Fees

 

		C.3.1	As
                                            partial consideration for this Agreement, LICENSEE will pay to LLNS a non-refundable
                                            U.S. Patent Maintenance Fee of Forty-Five Thousand Dollars ($45,000) (“U.S. Patent
                                            Maintenance Fee”) to be paid as follows.

 

		C.3.1.1	Fifteen
                                            Thousand Dollars ($15,000) to be paid on or before February 28, 2016;

 

		C.3.1.2	Fifteen
                                            Thousand Dollars ($15,000) to be paid on or before February 28, 2019; and

 

		C.3.1.3	Fifteen
                                            Thousand Dollars ($15,000) to be paid on or before February 28, 2023.

 

		C.3.2	The
                                            U.S. Patent Maintenance Fee will not be credited against any other royalty or fee due from
                                            LICENSEE to LLNS.

 

		C.4	Minimum
                                            Annual Royalties

 

		C.4.1	LICENSEE
                                            will pay to LLNS a minimum annual royalty according to the requirements of Article 5
                                            and the schedule below. The minimum annual royalty paid to LLNS during a calendar year will
                                            be credited against the earned royalty due and owing for the calendar year in which the minimum
                                            payment was made.

 

    
	15GM0520	29	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

	Calendar year	Minimum
    annual royalty	Due
    date
	2017	$5,000	February 28,
    2017
	2018	$10,000	February 28,
    2018
	2019	$10,000	February 28,
    2019
	2020
    

    and thereafter for the life of this Agreement	$25,000	February 28,
    2020 and every February 28 thereafter for the life of this Agreement

 

		C.4.2	LICENSEE
                                            will pay to LLNS Fifty Percent (50%) of any minimum annual royalty received from sublicensees.

 

		C.5	Assignment
                                            Fee

 

LICENSEE will pay LLNS an Assignment
Fee of One Hundred Thousand Dollars ($100,000) as per Article 19 (ASSIGNABILITY) prior to such assignment being executed by LLNS.

 

    
	15GM0520	30	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

Exhibit D
- Mutual Nondisclosure Agreement

 

    
	15GM0520	31	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

MUTUAL NONDISCLOSURE
AGREEMENT FOR EXCHANGE OF INFORMATION

 

This Agreement, effective on the date the last
party signs, is made by and between BIONOMICS DIAGNOSTICS located at [Redacted - Address] and LAWRENCE LIVERMORE NATIONAL
SECURITY, LLC, (“LLNS”), under its Contract No. DE-AC52-07NA27344 with the U.S. DEPARTMENT OF ENERGY (“DOE”),
to manage and operate the LAWRENCE LIVERMORE NATIONAL LABORATORY (“LLNL”), located at 7000 East Avenue, Livermore, CA 94550.

 

WHEREAS LLNS, as manager and operator of LLNL.
and BIONOMICS DIAGNOSTICS (hereinafter individually referred to as the “PARTY” or collectively as the “PARTIES”)
wish to exchange certain confidential and proprietary information relating to LLNL’s diagnostic kiosk technology portfolio (IL-11738, IL-11778,
and IL-11901) and BIONOMICS DIAGNOSTICS’ business and technology plans related to the diagnostic kiosk technology (“PROPRIETARY
INFORMATION”), this Agreement will govern the conditions of mutual disclosure of PROPRIETARY INFORMATION by the PARTIES.

 

The PARTIES hereby agree:

 

		(1)	To
                                            perform all terms of this Agreement and to maintain the PROPRIETARY INFORMATION in confidence,
                                            giving it the same degree of care, but no less than a reasonable degree of care, as the receiving
                                            PARTY exercises with its own proprietary information to prevent its unauthorized disclosure.

 

		(2)	To
                                            exchange and use the PROPRIETARY INFORMATION solely for the purpose of evaluation, testing,
                                            and development of potential collaborations, and/or license of the technology.

 

		(3)	Neither
                                            PARTY, without the prior written consent of the other, will disclose any portion of the PROPRIETARY
                                            INFORMATION to others except to their employees, agents, consultants, subcontractors or Government
                                            personnel having a need to know in order to accomplish the sole purpose stated above, and
                                            who are bound by a like obligation of confidentiality under this Agreement.

 

		(4)	Neither
                                            PARTY will have any obligation or assume any liability with respect to any portion of the
                                            PROPRIETARY INFORMATION that:

 

		a.	the
                                            receiving PARTY can demonstrate by written record was previously known to it;

 

		b.	is,
                                            or becomes, available to the public through no fault of the receiving PARTY:

 

		c.	is
                                            lawfully obtained by the receiving PARTY from a third party not under an obligation of confidence
                                            to the other PARTY;

 

		d.	is
                                            independently developed by or for the PARTY independent of any disclosure hereunder; or

 

		e.	is
                                            required to be disclosed to comply with applicable laws or government regulations, provided
                                            that prior written notice is given to the disclosing PARTY.

 

		(5)	PROPRIETARY
                                            INFORMATION disclosed by the PARTIES will be in writing and clearly marked “PROPRIETARY
                                            INFORMATION” or its equivalent. If such PROPRIETARY INFORMATION is initially disclosed
                                            orally or by demonstration, it will be identified as PROPRIETARY INFORMATION or its equivalent
                                            at the time of disclosure. The disclosing PARTY will, within thirty (30) days thereafter:
                                            (a) reduce such PROPRIETARY INFORMATION to writing or other tangible form, referencing
                                            the date and type of PROPRIETARY INFORMATION disclosed, and mark it as PROPRIETARY INFORMATION
                                            or its equivalent; and (b) deliver a copy to the receiving PARTY. All protections and
                                            restrictions as to use and disclosure will apply during such thirty (30) day period.

 

    
	15GM0520	32	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

		(6)	All
                                            rights and title to the PROPRIETARY INFORMATION disclosed under this Agreement will remain
                                            the property of disclosing PARTY unless otherwise agreed to in writing by the PARTIES.

 

		(7)	PROPRIETARY
                                            INFORMATION provided by any disclosing PARTY to any receiving PARTY shall be returned to
                                            the disclosing PARTY within five (5) days of written request for such return by the
                                            disclosing PARTY.

 

		(8)	No
                                            copies shall be made by a receiving PARTY of any PROPRIETARY INFORMATION without the express
                                            written consent of the disclosing PARTY. Any copies so authorized shall be returned to the
                                            disclosing PARTY or destroyed in accordance with the term and demand provisions of this Agreement,

 

		(9)	The
                                            RECIPIENT agrees that with regard to any patent application provided as PROPRIETARY INFORMATION
                                            under this Agreement that no action impeding issuance of any patent based on the disclosed
                                            application shall be filed or otherwise taken by RECIPIENT prior to publication of such patent
                                            application.

 

	Bionomics Diagnostics Contact:

     
	LLNL Contact:
	Name:	Paul Dadwal, President	Name:	Genaro Mempin
	Address:	[Redacted]
	Address:	7000 East Avenue

    Livermore, CA 94550

	Phone:	[Redacted]	Phone:	925 423 1121
	Email:	[Redacted]	Email:	Mempinl@linl.gov

 

It is further agreed that the furnishing of PROPRIETARY
INFORMATION does not constitute any grant or license to the other PARTY for any legal rights now or hereinafter held by either PARTY.

 

Unless terminated earlier by thirty (30) days
written notice by either PARTY to the other, this Agreement will remain in effect for two (2) years from the effective date, at
which time the receiving PARTY will return or destroy the PROPRIETARY INFORMATION within thirty (30) days of the termination of this
Agreement. If the PROPRIETARY INFORMATION is destroyed, a certificate of destruction must be furnished to the disclosing PARTY within
the thirty (30) days, The secrecy and non-use obligations of the receiving PARTY set forth above will remain in effect for five (5) years
from the effective date.

 

Each PARTY to this Agreement will be responsible
for the compliance to the export control laws and regulations of their respective countries.

 

Any photocopy or facsimile copy of this fully-executed
Agreement shall have the same legal force and effect as any copy bearing original signatures of the PARTIES.

 

Any modification to this Agreement must be in
writing and signed by the duly authorized representative of each PARTY.

 

    
	15GM0520	33	     TL02679-0.0

 

     

    

 

	Bionomics Diagnostics	Diagnostic Kiosk

 

LAWRENCE LIVERMORE NATIONAL SECURITY, LLC,

LAWRENCE LIVERMORE NATIONAL LABORATORY

 

	Signature:	/s/ Nina Potter	 
	Name: Nina Potter
	Title: IP and Agreements Management
	Industrial Partnerships Office

 

	Date:	04/02/2015	 

 

BIONOMICS DIAGNO

 

 

	Signature:    	/s/
    Poul Dadwal	 
	 	Name: Poul Dadwal	 
	 	Title: President	 
	 	 	 
	Date:	03/02/2015	 

 

	RETURN TO:	 	Lawrence Livermore National Laboratory
	 	 	ATTN: Terry Contreras L-795
	 	 	7000 East Avenue
	 	 	Livermore, CA 94550
	 	 	Phone 925 422 1511: Fax 925 423 8988
	 	 	Contreras1 @llnl.gov

 

    
	15GM0520	34	     TL02679-0.0Exhibit 10.6

 

AMENDMENT ONE

To

LIMITED EXCLUSIVE

PATENT LICENSE AGREEMENT

 

For

 

DIAGNOSTIC KIOSK

For Food Safety, Water Quality Monitoring, and

Human/Veterinary Clinical Diagnostics

 

Between

 

LAWRENCE LIVERMORE NATIONAL SECURITY, LLC

 

and

 

BIONOMICS DIAGNOSTICS, INC.,

a wholly-owned subsidiary of LexaGene Holdings, Inc.

 

LLNL Case No. TL02679.1

 

Lawrence Livermore National Laboratory

Industrial Partnerships Office

P.O. Box 808, L-795, Livermore, CA 94551

 

February 1, 2017

 

     

     

    

 

AMENDMENT ONE

February 1, 2017

 

to

 

License Agreement - LLNL Case Number TL02679.0

for Diagnostic Kiosk

between Bionomics Diagnostics, Inc. and Lawrence Livermore National Security, LLC

effective June 22, 2015

 

This Amendment One to the License Agreement by and between Lawrence
Livermore National Security, LLC (“LLNS”) and Bionomics Diagnostics, Inc. (“LICENSEE”) is effective as
of the date of execution of this Amendment by the last signing Party. This Amendment and the associated License Agreement are subject
to overriding obligations to the Federal Government pursuant to the provisions of LLNS’s Contract No DE-AC52-07NA27344 with the
United States Department of Energy (“DOE”) for the operation of the Lawrence Livermore National Laboratory (“LLNL”).

 

This Amendment One will update: 1) the company name and contact information,
and 2) Exhibit B (RIGHTS GRANTED AN PERFORMANCE OBLIGATIONS), to modify the Field of Use. All other terms and conditions remain the same.

 

Therefore, in consideration of the mutual covenants and obligations
recited herein, LLNS and LICENSEE hereby amend the License Agreement as follows:

 

		1.	Title Page and throughout (Company Name Change and Field of Use)

 

Delete:

 

For ENVIRONMENT AL SURVEILLANCE, FOOD TESTING,

AND HUMAN CLINICAL DIAGNOSTICS

 

Replace with:

 

For FOOD SAFETY, WATER QUALITY MONITORING, AND

HUMAN/VETERINARY CLINICAL DIAGNOSTICS

 

     

     

    

 

	Bionomics Diagnostics, Inc. , a wholly-owned subsidiary 	Diagnostic Kiosk
	LexaGene Holdings, Inc.	Amendment One

 

Delete throughout:

 

Bionomics Diagnostics

 

Replace with:

 

Bionomics Diagnostics, a wholly-owned subsidiary of LexaGene
Holdings, Inc.

 

		2.	Introductory Paragraph

 

Delete:

 

... and Bionomics Diagnostics, Inc. (“LICENSEE”)
a Canadian corporation having its principal place of business at 16473 92A Avenue, Surrey, British Columbia, V4N 5Nl , Canada.

 

Replace with:

 

... and Bionomics Diagnostics, Inc., a wholly-owned subsidiary of LexaGene
Holdings Inc. (“LICENSEE”) a Canadian corporation having its principal place of business at Suite 303, 750 West Pender
Street, Vancouver , British Columbia, V6C 2T7, Canada.

 

		3.	NOTICES

 

Delete:

 

	In the case of LICENSEE:	
    Bionomics Diagnostics, Inc.

    Suite 700 - 595 Burrard Street

    Vancouver , BC V7X 1S8 Canada

    Attention: Director

    Phone: (604) 771-7485

     

Replace with:

 

	In the case of LICENSEE:	
    Bionomics Diagnostics, Inc., a wholly owned 

subsidiary LexaGene
    Holdings, Inc.

    Suite 303, 750 West Pender Street

    Vancouver, BC V6C 2T7 Canada

    Attention: Dr. Jack Regan

    Phone: (604) 681-0084

    Fax: (604) 681-0094

 

     

     

    

 

	Bionomics Diagnostics, Inc. , a wholly-owned subsidiary 	Diagnostic Kiosk
	LexaGene Holdings, Inc.	Amendment One

 

		4.	Exhibit B (RIGHTS GRANTED AN PERFORMANCE OBLIGATIONS), Paragraph B.l

 

Delete:

 

“Field of Use” means Environmental Surveillance,
Food Testing, and Human Clinical Diagnostics.

 

Replace with:

 

“Field of Use” means Food Safety, Water Quality
Monitoring, and Human/Veterinary Clinical Diagnostics.

 

LLNS and LICENSEE execute this Amendment in duplicate originals,
by their respective officers who are duly authorized on the day and year that is written.

 

 

 

	BIONOMICS DIAGNOSTICS, INC., a wholly-owned subsidiary of LexaGene Holdings, Inc.	 	LAWRENCE LIVERMORE NATIONAL SECURITY, LLC LAWRENCE LIVERMORE NATIONAL LABORATORY
	 	 	 
	By:	/s/ John Regan	 	By:	/s/ Richard Rankin
	 	 	 	 	 
	Name:	John Regan	 	Name:	Richard A. Rankin
	 	 	 	 	 
	Title:	CEO	 	Title:	Director, Industrial Partnership Office
	 	 	 	 	 
	Date:	2/1/2017	 	Date:	2/6/2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]